Discovery of a non-nucleotide stimulator of interferon genes (STING) agonist with systemic antitumor effect

Abstract

Agonists of the stimulator of interferon genes (STING) pathway are increasingly being recognized as a promising new approach in the treatment of cancer. Although progress in clinical trials for STING agonists in antitumor applications has been slow, there is still an urgent need for developing new potent STING agonists with versatile potential applications. Herein, we developed and identified a non-nucleotide STING agonist called DW18343. DW18343 showed robust activation across different STING isoforms. Crystallography analysis revealed that DW18343 binds more deeply into the ligand binding domain (LBD) pocket of STING-H232 compared to other agonists such as MSA-2, SR-717, or cGAMP, which likely contributes to its high potency. DW18343 triggered downstream p-TBK1/p-IRF3 signaling, leading to the production of multiple cytokines. Additionally, DW18343 displayed broad and long-lasting antitumor effects in various syngeneic mouse tumor models, whether administered locally or systemically. Moreover, DW18343 induced immune memory to combat the growth of rechallenged tumors. Finally, DW18343 was shown to be an activator of both the innate and adaptive antitumor immunity in tumor tissue, potentially explaining its strong antitumor effects in vivo. In conclusion, DW18343 serves as a novel non-nucleotide STING agonist with systemic antitumor effect through the activation of antitumor immunity.

Keywords

antitumor / immune memory / innate immunity / STING agonist

References

[1] Scott EC, Baines AC, Gong Y, et al. Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat Rev Drug Discovery. 2023; 22(8): 625-640.

[2] Naimi A, Mohammed RN, Raji A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022; 20(1): 44.

[3] Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4): 69.

[4] Carpenter S, O’Neill LAJ. From periphery to center stage: 50 years of advancements in innate immunity. Cell. 2024; 187(9): 2030-2051.

[5] Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING agonists as cancer therapeutics. Cancers (Basel). 2021; 13(11).

[6] Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol Cancer. 2019; 18(1): 152.

[7] Su T, Zhang Y, Valerie K, Wang XY, Lin S, Zhu G. STING activation in cancer immunotherapy. Theranostics. 2019; 9(25): 7759-7771.

[8] Vashi N, Bakhoum SF. The evolution of STING signaling and its involvement in cancer. Trends Biochem Sci. 2021; 46(6): 446-460.

[9] Zhang X, Shi H, Wu J, et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell. 2013; 51(2): 226-235.

[10] Xie Z, Wang Z, Fan F, et al. Structural insights into a shared mechanism of human STING activation by a potent agonist and an autoimmune disease-associated mutation. Cell Discov. 2022; 8(1): 133.

[11] Lu D, Shang G, Li J, Lu Y, Bai XC, Zhang X. Activation of STING by targeting a pocket in the transmembrane domain. Nature. 2022.

[12] Corrales L, McWhirter SM, Dubensky TW, Jr, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016; 126(7): 2404-2411.

[13] Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022; 3(12): 1452-1463.

[14] Diamond MS, Kinder M, Matsushita H, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011; 208(10): 1989-2003.

[15] Li W, Lu L, Lu J, et al. cGAS-STING-mediated DNA sensing maintains CD8(+) T cell stemness and promotes antitumor T cell therapy. Sci Transl Med. 2020; 12(549).

[16] Vanpouille-Box C, Demaria S, Formenti SC, Galluzzi L. Cytosolic DNA sensing in organismal tumor control. Cancer Cell. 2018; 34(3): 361-378.

[17] Marcus AMA, Lensink-Vasan M, Wang L, Vance RE, Raulet DH. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity. 2018; 49(4): 754-763.

[18] Gaidt MM, Ebert TS, Chauhan D, et al. The DNA inflammasome in human myeloid cells is initiated by a STING-Cell death program upstream of NLRP3. Cell. 2017; 171(5): 1110-1124.e18.

[19] Gui X, Yang H, Li T, et al. Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature. 2019; 567(7747): 262-266.

[20] Zhang L, Jiang C, Zhong Y, et al. STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2. Nat Cell Biol. 2023; 25(8): 1208-1222.

[21] Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015; 11(7): 1018-1030.

[22] Sivick KE, Desbien AL, Glickman LH, et al. Magnitude of therapeutic sting activation determines CD8(+) T cell-mediated anti-tumor immunity. Cell Rep. 2018; 25(11): 3074-3085.

[23] Xing Y, Peng A, Yang J, et al. Precisely Activating cGAS-STING pathway with a novel peptide-based nanoagonist to potentiate immune Checkpoint blockade cancer immunotherapy. Adv Sci (Weinh). 2024:e2309583.

[24] Yang H, Lee WS, Kong SJ, et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest. 2019; 130: 4350-4364.

[25] Kosaka A, Ishibashi K, Nagato T, et al. CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. J Exp Med. 2021; 218(11).

[26] Wang XSA, Zhang Y, Chen X, et al. A novel STING agonist with systemic and durable anti-tumour activity. Clin Transl Disc. 2023; 3: e231.

[27] Pharmacological activation of STING blocks SARS-CoV-2 infection. Sci Immunol. 2021; 6(59)

[28] Wang C, Guan Y, Lv M, et al. Manganese Increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses. Immunity. 2018; 48(4): 675-687.e7.

[29] Van Herck S, Feng B, Tang L. Delivery of STING agonists for adjuvanting subunit vaccines. Adv Drug Deliv Rev. 2021; 179: 114020.

[30] Gogoi H, Mansouri S, Jin L. The age of cyclic dinucleotide vaccine adjuvants. Vaccines (Basel). 2020; 8(3).

[31] Chang W, Altman MD, Lesburg CA, et al. Discovery of MK-1454: a potent cyclic dinucleotide stimulator of interferon genes agonist for the Treatment of cancer. J Med Chem. 2022; 65(7): 5675-5689.

[32] Ramanjulu JM, Pesiridis GS, Yang J, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018.

[33] Pan BS, Perera SA, Piesvaux JA, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020; 369(6506).

[34] Chin EN, Yu C, Vartabedian VF, et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science. 2020; 369(6506): 993-999.

[35] Carideo Cunniff E, Sato Y, Mai D, et al. TAK-676: a novel stimulator of interferon genes (STING) agonist promoting durable IFN-dependent antitumor immunity in preclinical studies. Cancer Res Commun. 2022; 2(6): 489-502.

[36] Bao P, Gu HY, Ye JJ, et al. Chimeric exosomes functionalized with STING activation for personalized glioblastoma immunotherapy. Adv Sci (Weinh). 2023:e2306336.

[37] Leventhal DS, Sokolovska A, Li N, et al. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020; 11(1): 2739.

[38] Jiang Y, Li X, Qian F, et al. Fine-tuning Bacterial cyclic di-AMP production for durable antitumor effects through the activation of the STING pathway. Research (Wash D C). 2023; 6: 0102.

[39] Meric-Bernstam F, Sweis RF, Hodi FS, et al. Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas. Clin Cancer Res. 2022; 28(4): 677-688.

[40] Meric-Bernstam F, Sweis RF, Kasper S, et al. Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study. Clin Cancer Res. 2023; 29(1): 110-121.

[41] Luke JJ, Piha-Paul SA, Medina T, et al. Phase I study of SYNB1891, an engineered E. coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clin Cancer Res. 2023: OF1-OF10.

[42] Conlon J, Burdette DL, Sharma S, et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5, 6-dimethylxanthenone-4-acetic acid. J Immunol. 2013; 190(10): 5216-5225.

[43] Shen A, Li X, Zhang Y, et al. Structure-activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists. Eur J Med Chem. 2022; 241: 114627.

[44] Fuertes MB, Kacha AK, Kline J, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011; 208(10): 2005-2016.

[45] Ohkuri T, Ghosh A, Kosaka A, et al. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res. 2014; 2(12): 1199-1208.

[46] Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015; 36(12): 763-777.

[47] Mirlekar B, Pylayeva-Gupta Y. IL-12 Family cytokines in cancer and immunotherapy. Cancers (Basel). 2021; 13(2).

[48] Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation—a target for novel cancer therapy. Cancer Treat Rev. 2018; 63: 40-47.

[49] Shanahan CA, Gaffney BL, Jones RA, Strobel SA. Identification of c-di-GMP derivatives resistant to an EAL domain phosphodiesterase. Biochemistry. 2013; 52(2): 365-377.

[50] Wu YT, Fang Y, Wei Q, et al. Tumor-targeted delivery of a STING agonist improves cancer immunotherapy. Proc Nat Acad Sci USA. 2022; 119(49): e2214278119.

[51] Duvall JR, Thomas JD, Bukhalid RA, et al. Discovery and optimization of a STING agonist platform for application in antibody drug conjugates. J Med Chem. 2023; 66(15): 10715-10733.

[52] Bartneck J, Hartmann AK, Stein L, et al. Tumor-infiltrating CCR2(+) inflammatory monocytes counteract specific immunotherapy. Front Immunol. 2023; 14: 1267866.

[53] Weiss JM, Guerin MV, Regnier F, et al. The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression. Oncoimmunology. 2017; 6(10): e1346765.

[54] Wu K, Lin K, Li X, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol. 2020; 11: 1731.

[55] Gulen MF, Koch U, Haag SM, et al. Signalling strength determines proapoptotic functions of STING. Nat Commun. 2017; 8(1): 427.

[56] Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997; 276: 307-326.

[57] Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D. 2004; 60: 2126-2132.

[58] Adams PD, Afonine PV, Bunkoczi G, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010; 66(2): 213-221. Pt.

[59] Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011; 51(10): 2778-2786.

[60] Niu J, Bai H, Li Z, et al. Discovery of novel Thieno[2, 3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration. Eur J Med Chem. 2022; 238: 114482.

[61] Wang X, Shen A, Zhang Y, et al. A novel STING agonist with systemic and durable anti-tumour activity. Clin Transl Dis. 2023; 3(5).

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.